Table 1. Baseline Characteristics of the 18 SFTS Confirmed Cases.
| Characteristics | Total (n=18) | Survival (n=14) | Mortality (n=4) | p value |
|---|---|---|---|---|
| Gender, male | 9 (50.0) | 8 (57.1) | 1 (25.0) | 0.576* |
| Age, median year (IQR) | 74 (66, 77) | 72 (66, 77) | 76 (62, 83) | 0.534† |
| Hospital days (IQR) | 12 (6, 17) | 12 (6, 18) | 10 (5, 15) | 0.464† |
| Confirmed insect bite | 12 (66.7) | 10 (71.4) | 2 (50.0) | 0.569* |
| Underlying comorbidities | ||||
| Diabetes mellitus | 4 (22.2) | 3 (21.4) | 1 (25.0) | 1.000* |
| Cardiovascular | 7 (38.9) | 4 (28.6) | 3 (75.0) | 0.245* |
| Liver disease | 2 (11.1) | 1 (7.1) | 1 (25.0) | 0.405* |
| Renal disease | 1 (5.6) | 1 (7.1) | 0 (0) | 1.000* |
| Solid organ cancer | 2 (11.1) | 2 (14.3) | 0 (0) | 1.000* |
| Complication | ||||
| Meningoencephalitis | 4 (22.2) | 3 (21.4) | 1 (25.0) | 1.000* |
| Ventilator care | 3 (16.7) | 1 (7.1) | 2 (50.0) | 0.108* |
| Arrhythmia | 1 (5.6) | 1 (7.1) | 0 (0) | 1.000* |
| Bleeding | 1 (5.6) | 2 (11.1) | 1 (25.0) | 0.222* |
| Hemodialysis | 2 (11.1) | 2 (14.3) | 0 (0) | 1.000* |
| Treatment | ||||
| Plasmapheresis | 6 (33.3) | 4 (28.6) | 2 (50.0) | 0.569* |
| Ribavirin | 8 (44.4) | 6 (42.9) | 2 (50.0) | 1.000* |
| Interferon | 4 (22.2) | 2 (14.3) | 2 (50.0) | 0.197* |
| IVIG | 3 (16.7) | 2 (14.3) | 1 (25.0) | 1.000* |
| Cyclosporine | 1 (5.6) | 0 (0) | 1 (25.0) | 0.222* |
| Etoposide (VP-16) | 1 (5.6) | 0 (0) | 1 (25.0) | 0.222* |
| Available laboratory test results | ||||
| CBC | 18 (100) | 14 (100) | 4 (100) | |
| Triglyceride | 18 (100) | 14 (100) | 4 (100) | |
| Ferritin | 16 (88.9) | 12 (85.7) | 4 (100) | 1.000* |
| Bone marrow examination | 9 (50.0) | 5 (35.7) | 4 (100) | 0.082* |
| The HLH-2004 criteria | ||||
| Fever | 18 (100) | 14 (100) | 4 (100) | |
| Splenomegaly | 0 (0) | 0 (0) | 0 (0) | |
| Hemophagocytosis | 9 (50.0) | 5 (35.7) | 4 (100) | 0.082* |
| Cytopenia | 16 (88.9) | 12 (85.7) | 4 (100) | 1.000* |
| Hypertriglyceridemia | 12 (66.7) | 9 (64.3) | 3 (75.0) | 1.000* |
| Hyperferritinemia | 14 (87.5) | 10 (83.3) | 4 (100) | 1.000* |
| No. cases with five or more factors corresponding to 2004-HLH criteria | 6 (33.3) | 3 (21.4) | 3 (75.0) | 0.083* |
IVIG, intravenous immunoglobulin; HLH, hemophagocytic lymphohistiocytosis; SFTS, severe fever with thrombocytopenia syndrome; CBC, complete blood count; IQR, interquartile range.
The data were expressed as the number of patients (%) or median (IQR).
*Fisher's exact test was performed, †Mann-Whitney U-test was performed.